Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

112 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Fetuin-A, inter-α-trypsin inhibitor, glutamic acid and ChoE (18:0) are key biomarkers in a panel distinguishing mild from critical coronavirus disease 2019 outcomes.
Reverté L, Yeregui E, Olona M, Gutiérrez-Valencia A, Buzón MJ, Martí A, Gómez-Bertomeu F, Auguet T, López-Cortés LF, Burgos J, Benavent-Bofill C, Boqué C, García-Pardo G, Ruiz-Mateos E, Mestre MT, Vidal F, Viladés C, Peraire J, Rull A; COVIDOMICS Study Group. Reverté L, et al. Among authors: vilades c. Clin Transl Med. 2022 Jan;12(1):e704. doi: 10.1002/ctm2.704. Clin Transl Med. 2022. PMID: 35075803 Free PMC article. No abstract available.
Lack of association of SDF-1 3'A variant allele with long-term nonprogressive HIV-1 infection is extended beyond 16 years.
Vidal F, Peraire J, Domingo P, Broch M, Knobel H, Pedrol E, Dalmau D, Viladés C, Sambeat MA, Gutiérrez C, Richart C; Chemokines and Long-Term Nonprogressor Study Group. Vidal F, et al. Among authors: vilades c. J Acquir Immune Defic Syndr. 2005 Nov 1;40(3):276-9. doi: 10.1097/01.qai.0000176653.89769.4d. J Acquir Immune Defic Syndr. 2005. PMID: 16249700
Spanish HIV-1-infected long-term nonprogressors of more than 15 years have an increased frequency of the CX3CR1 249I variant allele.
Vidal F, Viladés C, Domingo P, Broch M, Pedrol E, Dalmau D, Knobel H, Peraire J, Gutiérrez C, Sambeat MA, Fontanet A, Deig E, Cairó M, Montero M, Richart C, Mallal S; Chemokines LTNP Study Group. Vidal F, et al. Among authors: vilades c. J Acquir Immune Defic Syndr. 2005 Dec 15;40(5):527-31. doi: 10.1097/01.qai.0000186362.50457.e0. J Acquir Immune Defic Syndr. 2005. PMID: 16284527
Polymorphism of RANTES chemokine gene promoter is not associated with long-term nonprogressive HIV-1 infection of more than 16 years.
Vidal F, Peraire J, Domingo P, Broch M, Cairó M, Pedrol E, Montero M, Viladés C, Gutiérrez C, Sambeat MA, Fontanet A, Dalmau D, Deig E, Knobel H, Sirvent JJ, Richart C, Veloso S, Saumoy M, López-Dupla M, Olona M, Cadafalch J, Fuster M, Ochoa A, Soler A, Guelar A, González J; Chemokines and Long-Term Nonprogressive HIV01 Infection Study Group. Vidal F, et al. Among authors: vilades c. J Acquir Immune Defic Syndr. 2006 Jan 1;41(1):17-22. doi: 10.1097/01.qai.0000188335.86466.ea. J Acquir Immune Defic Syndr. 2006. PMID: 16340468
Effect of genetic variants of CCR2 and CCL2 on the natural history of HIV-1 infection: CCL2-2518GG is overrepresented in a cohort of Spanish HIV-1-infected subjects.
Viladés C, Broch M, Plana M, Domingo P, Alonso-Villaverde C, Pedrol E, Knobel H, Dalmau D, Peraire J, Gutiérrez C, López A, Sambeat MA, Olona M, Garcia F, Richart C, Gatell JM, Vidal F; Chemokines and Long-Term Nonprogressors Study Group. Viladés C, et al. J Acquir Immune Defic Syndr. 2007 Feb 1;44(2):132-8. doi: 10.1097/QAI.0b013e31802b3147. J Acquir Immune Defic Syndr. 2007. PMID: 17091019
PPARgamma Pro12Ala polymorphism in HIV-1-infected patients with HAART-related lipodystrophy.
Saumoy M, Veloso S, Alonso-Villaverde C, Domingo P, Chacón MR, Miranda M, Aragonès G, Gutiérrez MM, Viladés C, Peraire J, Sirvent JJ, López-Dupla M, Aguilar C, Richart C, Vidal F; HIV Lipodystrophy Study Group. Saumoy M, et al. Among authors: vilades c. Curr HIV Res. 2009 Sep;7(5):533-40. doi: 10.2174/157016209789346219. Curr HIV Res. 2009. PMID: 19534662
Pharmacogenetics of adverse effects due to antiretroviral drugs.
Vidal F, Gutiérrez F, Gutiérrez M, Olona M, Sánchez V, Mateo G, Peraire J, Viladés C, Veloso S, López-Dupla M, Domingo P. Vidal F, et al. Among authors: vilades c. AIDS Rev. 2010 Jan-Mar;12(1):15-30. AIDS Rev. 2010. PMID: 20216907 Review.
Effect of TNF-alpha genetic variants and CCR5 Delta 32 on the vulnerability to HIV-1 infection and disease progression in Caucasian Spaniards.
Veloso S, Olona M, García F, Domingo P, Alonso-Villaverde C, Broch M, Peraire J, Viladés C, Plana M, Pedrol E, López-Dupla M, Aguilar C, Gutiérrez M, Leon A, Tasias M, Gatell JM, Richart C, Vidal F. Veloso S, et al. Among authors: vilades c. BMC Med Genet. 2010 Apr 26;11:63. doi: 10.1186/1471-2350-11-63. BMC Med Genet. 2010. PMID: 20420684 Free PMC article.
No relationship between TNF-α genetic variants and combination antiretroviral therapy-related lipodystrophy syndrome in HIV type 1-infected patients: a case-control study and a meta-analysis.
Veloso S, Olona M, Peraire J, Viladés C, Pardo P, Domingo P, Asensi V, Broch M, Aguilar C, López-Dupla M, Aragonés G, Garcia-Pardo G, Sirvent JJ, Vendrell J, Richart C, Vidal F; Hiv Lipodystrophy Study Group. Veloso S, et al. Among authors: vilades c. AIDS Res Hum Retroviruses. 2011 Feb;27(2):143-52. doi: 10.1089/aid.2009.0312. Epub 2010 Sep 20. AIDS Res Hum Retroviruses. 2011. PMID: 20854131
Lipodystrophy and insulin resistance in combination antiretroviral treated HIV-1-infected patients: implication of resistin.
Escoté X, Miranda M, Veloso S, Domingo P, Alonso-Villaverde C, Peraire J, Viladés C, Alba V, Olona M, Castro A, López-Dupla M, Sirvent JJ, Vicente V, Vendrell J, Richart C, Vidal F; HIV-1 Lipodystrophy Study Group. Escoté X, et al. Among authors: vilades c. J Acquir Immune Defic Syndr. 2011 May 1;57(1):16-23. doi: 10.1097/QAI.0b013e318213312c. J Acquir Immune Defic Syndr. 2011. PMID: 21317795
Most HIV type 1 non-B infections in the Spanish cohort of antiretroviral treatment-naïve HIV-infected patients (CoRIS) are due to recombinant viruses.
Yebra G, de Mulder M, Martín L, Rodríguez C, Labarga P, Viciana I, Berenguer J, Alemán MR, Pineda JA, García F, Holguín A; Cohort of the Spanish AIDS Research Network (CoRIS). Yebra G, et al. J Clin Microbiol. 2012 Feb;50(2):407-13. doi: 10.1128/JCM.05798-11. Epub 2011 Dec 7. J Clin Microbiol. 2012. PMID: 22162552 Free PMC article.
Adipogenic/lipid, inflammatory, and mitochondrial parameters in subcutaneous adipose tissue of untreated HIV-1-infected long-term nonprogressors: significant alterations despite low viral burden.
Vidal F, Domingo P, Villarroya F, Giralt M, López-Dupla M, Gutiérrez M, Gallego-Escuredo JM, Peraire J, Viladés C, Veloso S, Mateo G, Guallar JP, Richart C. Vidal F, et al. Among authors: vilades c. J Acquir Immune Defic Syndr. 2012 Oct 1;61(2):131-7. doi: 10.1097/QAI.0b013e31825c3a68. J Acquir Immune Defic Syndr. 2012. PMID: 22580565
Evaluation of the pharmacogenetics of immune recovery in treated HIV-infected patients.
Peraire J, Viladés C, Pacheco YM, López-Dupla M, Domingo P, Gutiérrez M, Rosado I, Leal M, Richart C, Vidal F. Peraire J, et al. Among authors: vilades c. Expert Opin Drug Metab Toxicol. 2014 Jan;10(1):81-101. doi: 10.1517/17425255.2014.854330. Epub 2013 Nov 21. Expert Opin Drug Metab Toxicol. 2014. PMID: 24256435 Review.
Involvement of the LPS-LPB-CD14-MD2-TLR4 inflammation pathway in HIV-1/HAART-associated lipodystrophy syndrome (HALS).
Viladés C, Escoté X, López-Dupla M, Martinez E, Domingo P, Asensi V, Leal M, Peraire J, Inza MI, Arnedo M, Gutiérrez M, Valle-Garay E, Ferrando-Martinez S, Olona M, Alba V, Sirvent JJ, Gatell JM, Vidal F; HALS Study Group. Viladés C, et al. J Antimicrob Chemother. 2014 Jun;69(6):1653-9. doi: 10.1093/jac/dku032. Epub 2014 Feb 16. J Antimicrob Chemother. 2014. PMID: 24535275
HIV-1/HAART-Related Lipodystrophy Syndrome (HALS) Is Associated with Decreased Circulating sTWEAK Levels.
López-Dupla M, Maymó-Masip E, Martínez E, Domingo P, Leal M, Peraire J, Viladés C, Veloso S, Arnedo M, Ferrando-Martínez S, Beltrán-Debón R, Alba V, Gatell JM, Vendrell J, Vidal F, Chacón MR. López-Dupla M, et al. Among authors: vilades c. PLoS One. 2015 Dec 14;10(12):e0144789. doi: 10.1371/journal.pone.0144789. eCollection 2015. PLoS One. 2015. PMID: 26658801 Free PMC article.
A baseline metabolomic signature is associated with immunological CD4+ T-cell recovery after 36 months of antiretroviral therapy in HIV-infected patients.
Rodríguez-Gallego E, Gómez J, Pacheco YM, Peraire J, Viladés C, Beltrán-Debón R, Mallol R, López-Dupla M, Veloso S, Alba V, Blanco J, Cañellas N, Rull A, Leal M, Correig X, Domingo P, Vidal F. Rodríguez-Gallego E, et al. Among authors: vilades c. AIDS. 2018 Mar 13;32(5):565-573. doi: 10.1097/QAD.0000000000001730. AIDS. 2018. PMID: 29280761 Free PMC article.
Circulating metabolomic profile can predict dyslipidemia in HIV patients undergoing antiretroviral therapy.
Rodríguez-Gallego E, Gómez J, Domingo P, Ferrando-Martínez S, Peraire J, Viladés C, Veloso S, López-Dupla M, Beltrán-Debón R, Alba V, Vargas M, Castellano AJ, Leal M, Pacheco YM, Ruiz-Mateos E, Gutiérrez F, Vidal F, Rull A; CORIS-NADES events Study Group. Rodríguez-Gallego E, et al. Among authors: vilades c. Atherosclerosis. 2018 Jun;273:28-36. doi: 10.1016/j.atherosclerosis.2018.04.008. Epub 2018 Apr 9. Atherosclerosis. 2018. PMID: 29677628 Free article.
Proteomic Profile Associated With Loss of Spontaneous Human Immunodeficiency Virus Type 1 Elite Control.
Rodríguez-Gallego E, Tarancón-Diez L, García F, Del Romero J, Benito JM, Alba V, Herrero P, Rull A, Dominguez-Molina B, Martinez-Madrid O, Martin-Pena L, Pulido F, León A, Rodríguez C, Rallón N, Peraire J, Viladés C, Leal M, Vidal F, Ruiz-Mateos E; HIV-1 Elite Controllers Study Group (ECRIS), Spanish AIDS Research Network. Rodríguez-Gallego E, et al. Among authors: vilades c. J Infect Dis. 2019 Feb 23;219(6):867-876. doi: 10.1093/infdis/jiy599. J Infect Dis. 2019. PMID: 30312441 Free article.
Immunometabolism is a key factor for the persistent spontaneous elite control of HIV-1 infection.
Tarancon-Diez L, Rodríguez-Gallego E, Rull A, Peraire J, Viladés C, Portilla I, Jimenez-Leon MR, Alba V, Herrero P, Leal M, Ruiz-Mateos E, Vidal F; ECRIS integrated in the Spanish AIDS Research Network. Tarancon-Diez L, et al. Among authors: vilades c. EBioMedicine. 2019 Apr;42:86-96. doi: 10.1016/j.ebiom.2019.03.004. Epub 2019 Mar 14. EBioMedicine. 2019. PMID: 30879922 Free PMC article.
Glutaminolysis and lipoproteins are key factors in late immune recovery in successfully treated HIV-infected patients.
Rosado-Sánchez I, Rodríguez-Gallego E, Peraire J, Viladés C, Herrero P, Fanjul F, Gutiérrez F, Bernal E, Pelazas R, Leal M, Veloso S, López-Dupla M, Blanco J, Vidal F, Pacheco YM, Rull A. Rosado-Sánchez I, et al. Among authors: vilades c. Clin Sci (Lond). 2019 Apr 29;133(8):997-1010. doi: 10.1042/CS20190111. Print 2019 Apr 30. Clin Sci (Lond). 2019. PMID: 30952809
IL-7/IL-7R gene variants impact circulating IL-7/IL-7R homeostasis and ART-associated immune recovery status.
Ceausu A, Rodríguez-Gallego E, Peraire J, López-Dupla M, Domingo P, Viladés C, Vidal-Gonzalez J, Peraire M, Perpiñán C, Pacheco YM, Veloso S, Alba V, Vargas M, Castellano AJ, Ruiz-Mateos E, Mallolas J, Vidal F, Rull A. Ceausu A, et al. Among authors: vilades c. Sci Rep. 2019 Oct 31;9(1):15722. doi: 10.1038/s41598-019-52025-8. Sci Rep. 2019. PMID: 31673011 Free PMC article.
Effectiveness of the combination elvitegravir/cobicistat/tenofovir/emtricitabine (EVG/COB/TFV/FTC) plus darunavir among treatment-experienced patients in clinical practice: a multicentre cohort study.
Suárez-García I, Moreno C, Ruiz-Algueró M, Pérez-Elías MJ, Navarro M, Díez Martínez M, Viciana P, Pérez-Martínez L, Górgolas M, Amador C, de Zárraga MA, Jarrín I; Cohort of the Spanish HIV/AIDS Research Network (CoRIS). Suárez-García I, et al. AIDS Res Ther. 2020 Jul 20;17(1):45. doi: 10.1186/s12981-020-00302-2. AIDS Res Ther. 2020. PMID: 32690099 Free PMC article.
Effects of first-line antiretroviral therapy on the CD4/CD8 ratio and CD8 cell counts in CoRIS: a prospective multicentre cohort study.
Serrano-Villar S, Martínez-Sanz J, Ron R, Talavera-Rodríguez A, Fernández-Felix BM, Herrera S, Muriel A, Fanjul F, Portilla J, Muñoz J, Amador C, de Zárraga MA, Vivancos MJ, Moreno S; Spanish HIV Research Network (CoRIS). Serrano-Villar S, et al. Lancet HIV. 2020 Aug;7(8):e565-e573. doi: 10.1016/S2352-3018(20)30202-2. Lancet HIV. 2020. PMID: 32763219 Clinical Trial.
High circulating SDF-1and MCP-1 levels and genetic variations in CXCL12, CCL2 and CCR5: Prognostic signature of immune recovery status in treated HIV-positive patients.
Yeregui E, Viladés C, Domingo P, Ceausu A, Pacheco YM, Veloso S, Inciarte A, Vidal-González J, Peraire M, Perpiñán C, Falcó V, Masip J, Alba V, Vargas M, Martí A, Reverté L, Mallolas J, Vidal F, Peraire J, Rull A. Yeregui E, et al. Among authors: vilades c. EBioMedicine. 2020 Dec;62:103077. doi: 10.1016/j.ebiom.2020.103077. Epub 2020 Nov 6. EBioMedicine. 2020. PMID: 33166788 Free PMC article.
Differential miRNA plasma profiles associated with the spontaneous loss of HIV-1 control: miR-199a-3p and its potential role as a biomarker for quick screening of elite controllers.
Masip J, Gasca-Capote C, Jimenez-Leon MR, Peraire J, Perez-Gomez A, Alba V, Malo AI, Leal L, Martín CR, Rallón N, Viladés C, Olona M, Vidal F, Ruiz-Mateos E, Rull A; ECRIS integrated in the Spanish AIDS Research Network (Annex S1). Masip J, et al. Among authors: vilades c. Clin Transl Med. 2021 Jul;11(7):e474. doi: 10.1002/ctm2.474. Clin Transl Med. 2021. PMID: 34323411 Free PMC article. No abstract available.
COVID-19 in hospitalized HIV-positive and HIV-negative patients: A matched study.
Díez C, Del Romero-Raposo J, Mican R, López JC, Blanco JR, Calzado S, Samperiz G, Portilla J, García-Fraile LJ, Gutiérrez F, Gómez-Sirvent JL, Suárez-García I, Amador C, Novella M, Arribas JR, Moreno S, González-García J, Jarrín I, Berenguer J; for CoRIS. Díez C, et al. HIV Med. 2021 Oct;22(9):867-876. doi: 10.1111/hiv.13145. Epub 2021 Jul 29. HIV Med. 2021. PMID: 34324783 Free PMC article.
Adipokines as New Biomarkers of Immune Recovery: Apelin Receptor, RBP4 and ZAG Are Related to CD4+ T-Cell Reconstitution in PLHIV on Suppressive Antiretroviral Therapy.
Yeregui E, Masip J, Viladés C, Domingo P, Pacheco YM, Blanco J, Mallolas J, Alba V, Vargas M, García-Pardo G, Negredo E, Olona M, Vidal-González J, Peraire M, Martí A, Reverté L, Gómez-Bertomeu F, Leal M, Vidal F, Peraire J, Rull A. Yeregui E, et al. Among authors: vilades c. Int J Mol Sci. 2022 Feb 17;23(4):2202. doi: 10.3390/ijms23042202. Int J Mol Sci. 2022. PMID: 35216318 Free PMC article.
Use of Generic Antiretroviral Drugs and Single-Tablet Regimen De-Simplification for the Treatment of HIV Infection in Spain.
Ruiz-Algueró M, Alejos B, García Yubero C, Riera Jaume M, Antonio Iribarren J, Asensi V, Pasquau F, Galera CE, Pascual-Carrasco M, Muñoz A, Jarrín I, Suárez-García I; CoRIS Cohort. Ruiz-Algueró M, et al. AIDS Res Hum Retroviruses. 2022 Jun;38(6):433-440. doi: 10.1089/AID.2021.0122. Epub 2022 May 2. AIDS Res Hum Retroviruses. 2022. PMID: 35357907
Elevated α-Ketoglutaric Acid Concentrations and a Lipid-Balanced Signature Are the Key Factors in Long-Term HIV Control.
Masip J, Rallón N, Yeregui E, Olona M, Resino S, Benito JM, Viladés C, García-Pardo G, Alcamí J, Ruiz-Mateos E, Gómez-Bertomeu F, Vargas M, Navarro M, Oteo JA, Pineda JA, Martí A, Alba V, Vidal F, Peraire J, Rull A. Masip J, et al. Among authors: vilades c. Front Immunol. 2022 Apr 20;13:822272. doi: 10.3389/fimmu.2022.822272. eCollection 2022. Front Immunol. 2022. PMID: 35514981 Free PMC article.
Transient Viral Rebound in Children with Perinatally Acquired HIV-1 Induces a Unique Soluble Immunometabolic Signature Associated with Decreased CD4/CD8 Ratio.
Tarancon-Diez L, Peraire J, Jiménez de Ory S, Guirro M, Escosa L, Prieto Tato LM, Penín Antón M, Piqueras AI, Vázquez Pérez Á, Gavilán C, Bustillo-Alonso M, Navarro ML, Viladés C, Vidal F, Rull A, Muñoz-Fernández MÁ. Tarancon-Diez L, et al. Among authors: vilades c. J Pediatric Infect Dis Soc. 2023 Apr 18;12(3):143-151. doi: 10.1093/jpids/piad008. J Pediatric Infect Dis Soc. 2023. PMID: 36727571 Free PMC article.
Effectiveness and tolerability of dolutegravir/lamivudine for the treatment of HIV-1 infection in clinical practice.
Suárez-García I, Alejos B, Hernando V, Viñuela L, Vera García M, Rial-Crestelo D, Pérez Elías MJ, Albendín Iglesias H, Peraire J, Tiraboschi J, Díaz A, Moreno S, Jarrín I; Cohort of the Spanish HIV/AIDS Research Network (CoRIS). Suárez-García I, et al. J Antimicrob Chemother. 2023 Jun 1;78(6):1423-1432. doi: 10.1093/jac/dkad102. J Antimicrob Chemother. 2023. PMID: 37099559 Free PMC article.
Cohort Profile: PISCIS, a population-based cohort of people living with HIV in Catalonia and Balearic Islands.
Bruguera A, Nomah D, Moreno-Fornés S, Díaz Y, Aceitón J, Reyes-Urueña J, Ambrosioni J, Llibre JM, Falcó V, Imaz A, Fanjul F, Navarro G, Pere D, León E, Mera A, Miró JM, Casabona J; PISCIS Cohort Group. Bruguera A, et al. Int J Epidemiol. 2023 Aug 2;52(4):e241-e252. doi: 10.1093/ije/dyad083. Int J Epidemiol. 2023. PMID: 37403345 No abstract available.
Multi-omics in HIV: searching insights to understand immunological non-response in PLHIV.
Espineira S, Flores-Piñas M, Chafino S, Viladés C, Negredo E, Fernández-Arroyo S, Mallolas J, Villar B, Moreno S, Vidal F, Rull A, Peraire J. Espineira S, et al. Among authors: vilades c. Front Immunol. 2023 Aug 15;14:1228795. doi: 10.3389/fimmu.2023.1228795. eCollection 2023. Front Immunol. 2023. PMID: 37649488 Free PMC article. Review.
The HIV-1 reservoir landscape in persistent elite controllers and transient elite controllers.
Gasca-Capote C, Lian X, Gao C, Roseto IC, Jiménez-León MR, Gladkov G, Camacho-Sojo MI, Pérez-Gómez A, Gallego I, Lopez-Cortes LE, Bachiller S, Vitalle J, Rafii-El-Idrissi Benhnia M, Ostos FJ, Collado-Romacho AR, Santos J, Palacios R, Gomez-Ayerbe C, Muñoz-Medina L, Ruiz-Sancho A, Frias M, Rivero-Juarez A, Roca-Oporto C, Hidalgo-Tenorio C, Rull A, Olalla J, Lopez-Ruz MA, Vidal F, Viladés C, Mastrangelo A, Cavassini M, Espinosa N, Perreau M, Peraire J, Rivero A, López-Cortes LF, Lichterfeld M, Yu XG, Ruiz-Mateos E. Gasca-Capote C, et al. Among authors: vilades c. J Clin Invest. 2024 Feb 20;134(8):e174215. doi: 10.1172/JCI174215. J Clin Invest. 2024. PMID: 38376918 Free PMC article.
Multiomics plasma effects of switching from triple antiretroviral regimens to dolutegravir plus lamivudine.
de Lazzari E, Negredo EB, Domingo P, Tiraboschi JM, Ribera E, Abdulghani N, Alba V, Fernández-Arroyo S, Viladés C, Peraire J, Gatell JM, Blanco JL, Vidal F, Rull A, Martinez E. de Lazzari E, et al. Among authors: vilades c. J Antimicrob Chemother. 2024 May 2;79(5):1133-1141. doi: 10.1093/jac/dkae083. J Antimicrob Chemother. 2024. PMID: 38546974 Free PMC article. Clinical Trial.
Should we measure quality of life among people with HIV? A multicentre survey of physicians' opinions in Spain.
Izquierdo R, Suárez-García I, Gómez-García T, Marco-Sánchez C, Puente-Ferreiro J, Moreno C, Diaz A, Cabello-Clotet N, Vinuesa D, Blanco JL, Melús E, Gómez-Ayerbe C, Olalla J, Riera M, Bernardino JI, de López Bernaldo de Quirós JC, Moreno S, Jarrín I; CoRIS cohort. Izquierdo R, et al. HIV Med. 2025 Feb;26(2):308-318. doi: 10.1111/hiv.13726. Epub 2024 Oct 25. HIV Med. 2025. PMID: 39455423 Free PMC article.
Long-term effectiveness and tolerability of dolutegravir/lamivudine in treatment-naive people with HIV: an analysis of a multicentre cohort at 96 weeks.
Suárez-García I, Alejos B, Moreno C, Martín Torres J, Masiá M, García-Fraile LJ, Riera M, Dalmau D, Rodríguez-Rosado R, Muga R, Moreno S, Jarrín I; CoRIS cohort. Suárez-García I, et al. J Antimicrob Chemother. 2025 Mar 3;80(3):682-691. doi: 10.1093/jac/dkae456. J Antimicrob Chemother. 2025. PMID: 39710424 Free PMC article.
Absence of CXCR4 C-terminal polymorphisms in HIV-1-infected and uninfected Spaniards.
Peraire J, Broch M, Domingo P, Pedrol E, Dalmau D, Knobel H, Viladés C, Sambeat MA, Richart C, Vidal F. Peraire J, et al. Among authors: vilades c. J Acquir Immune Defic Syndr. 2006 Jul;42(3):382-3. doi: 10.1097/01.qai.0000223019.86320.dc. J Acquir Immune Defic Syndr. 2006. PMID: 16763530 No abstract available.
Effectiveness and safety of didanosine, lamivudine and efavirenz versus zidovudine, lamivudine and efavirenz for the initial treatment of HIV-infected patients from the Spanish VACH cohort.
Crespo M, Ribera E, Suárez-Lozano I, Domingo P, Pedrol E, López-Aldeguer J, Muñoz A, Viladés C, Sánchez T, Viciana P, Teira R, García-Alcalde ML, Vergara A, Lozano F, Galindo MJ, Cosin J, Roca B, Terrón A, Geijo P, Vidal F, Garrido M; VACH Cohort Study Group. Crespo M, et al. Among authors: vilades c. J Antimicrob Chemother. 2009 Jan;63(1):189-96. doi: 10.1093/jac/dkn450. Epub 2008 Nov 6. J Antimicrob Chemother. 2009. PMID: 18988678 Clinical Trial.
Decrease in serial prevalence of coinfection with hepatitis C virus among HIV-infected patients in Spain, 1997-2006.
Pérez Cachafeiro S, Del Amo J, Iribarren JA, Salavert Lleti M, Gutiérrez F, Moreno A, Labarga P, Pineda JA, Vidal F, Berenguer J, Moreno S; Cohorts of the Spanish AIDS Research Network (CoRIS and CoRIS-MD). Pérez Cachafeiro S, et al. Clin Infect Dis. 2009 May 15;48(10):1467-70. doi: 10.1086/598333. Clin Infect Dis. 2009. PMID: 19368502
Efficacy and safety of switching from boosted lopinavir to boosted atazanavir in patients with virological suppression receiving a LPV/r-containing HAART: the ATAZIP study.
Mallolas J, Podzamczer D, Milinkovic A, Domingo P, Clotet B, Ribera E, Gutiérrez F, Knobel H, Cosin J, Ferrer E, Arranz JA, Roca V, Vidal F, Murillas J, Pich J, Pedrol E, Llibre JM, Dalmau D, García I, Aranda M, Cruceta A, Martínez E, Blanco JL, Lazzari Ed, Gatell JM; ATAZIP Study Group. Mallolas J, et al. J Acquir Immune Defic Syndr. 2009 May 1;51(1):29-36. doi: 10.1097/QAI.0b013e31819a226f. J Acquir Immune Defic Syndr. 2009. PMID: 19390327 Clinical Trial.
[The Cohort of the Spanish HIV Research Network (CoRIS) and its associated biobank; organizational issues, main findings and losses to follow-up].
Sobrino-Vegas P, Gutiérrez F, Berenguer J, Labarga P, García F, Alejos-Ferreras B, Muñoz MA, Moreno S, del Amo J; CoRIS. Sobrino-Vegas P, et al. Enferm Infecc Microbiol Clin. 2011 Nov;29(9):645-53. doi: 10.1016/j.eimc.2011.06.002. Epub 2011 Aug 5. Enferm Infecc Microbiol Clin. 2011. PMID: 21820763 Spanish.
Physicians' opinions on generic antiretroviral drugs and single-tablet regimen de-simplification for the treatment of HIV infection: a multicentre survey in Spain.
Suárez-García I, Ruiz-Algueró M, García Yubero C, Moreno C, Belza MJ, Estébanez M, de Los Santos I, Masiá M, Samperiz Abad G, Muñoz Sánchez J, Omar M, Jarrín I; Cohort of the Spanish HIV/AIDS Research Network (CoRIS). Suárez-García I, et al. J Antimicrob Chemother. 2020 Feb 1;75(2):466-472. doi: 10.1093/jac/dkz439. J Antimicrob Chemother. 2020. PMID: 31665404
Safety of Switching Nevirapine Twice Daily to Nevirapine Once Daily in Virologically Suppressed Patients.
Podzamczer D, Olmo M, Sanz J, Boix V, Negredo E, Knobel H, Domingo P, Pineda JA, Vilades C, Quero JH, Force L, Lahoz JG, Muñoz P, Llibre JM, Mariño A, Ortega E, Dalmau D, Gatell JM, Antón E, Sola J, Galindo MJ, Pedrol E, Sanz J, Lima JT, Flores J; NODy Study Group. Podzamczer D, et al. Among authors: vilades c. J Acquir Immune Defic Syndr. 2009 Apr 1;50(4):390-6. doi: 10.1097/QAI.0b013e318198a0cc. J Acquir Immune Defic Syndr. 2009. PMID: 19214120 Clinical Trial.
Slow growing painless mass in the lower limb.
Vidal-Gonzalez J, Peraire M, Perpiñán C, Viladés C. Vidal-Gonzalez J, et al. Among authors: vilades c. Enferm Infecc Microbiol Clin (Engl Ed). 2018 Mar;36(3):196-197. doi: 10.1016/j.eimc.2016.10.008. Epub 2016 Dec 12. Enferm Infecc Microbiol Clin (Engl Ed). 2018. PMID: 27979434 English, Spanish. No abstract available.
Antiretroviral treatment simplification with 3 NRTIs or 2 NRTIs plus nevirapine in HIV-1-infected patients treated with successful first-line HAART.
Bonjoch A, Paredes R, Galvez J, Miralles C, Videla S, Martínez E, Miranda J, Muñoz-Moreno JA, De la Torre J, Prieto A, Vilades C, Clotet B; SimplifiHAART Study Group. Bonjoch A, et al. Among authors: vilades c. J Acquir Immune Defic Syndr. 2005 Jul 1;39(3):313-6. doi: 10.1097/01.qai.0000164249.33851.3a. J Acquir Immune Defic Syndr. 2005. PMID: 15980691 Clinical Trial.
Heterogeneity in outcomes of treated HIV-positive patients in Europe and North America: relation with patient and cohort characteristics.
May MT, Hogg RS, Justice AC, Shepherd BE, Costagliola D, Ledergerber B, Thiébaut R, Gill MJ, Kirk O, van Sighem A, Saag MS, Navarro G, Sobrino-Vegas P, Lampe F, Ingle S, Guest JL, Crane HM, D'Arminio Monforte A, Vehreschild JJ, Sterne JA; Antiretroviral Therapy Cohort Collaboration (ART-CC). May MT, et al. Int J Epidemiol. 2012 Dec;41(6):1807-20. doi: 10.1093/ije/dys164. Epub 2012 Nov 12. Int J Epidemiol. 2012. PMID: 23148105 Free PMC article.
Health-related quality of life in people with HIV from the multicentre CoRIS cohort in Spain: Associated factors and short-term changes over time.
Izquierdo R, Suárez-García I, Marco-Sánchez C, Pérez-Latorre L, Riera M, Cano J, Viladés C, Reus S, Olalla J, González-Ruano P, Orviz E, Díaz A, Moreno S, Jarrín I; CoRIS cohort. Izquierdo R, et al. Among authors: vilades c. HIV Med. 2025 Apr;26(4):606-620. doi: 10.1111/hiv.13762. Epub 2025 Jan 21. HIV Med. 2025. PMID: 39835516 Free PMC article.
[Cardiovascular risk in human immunodeficiency virus-infected patients in Spain. CoRIS cohort, 2011].
Masiá M, Pérez-Cachafeiro S, Leyes M, López-Aldeguer J, López M, Segura F, Blanco JR, Peña A, Rodríguez F, Vera M, Del Amo J, Gutiérrez F; Grupo de estudio de riesgo cardiovascular de CoRIS. Masiá M, et al. Enferm Infecc Microbiol Clin. 2012 Nov;30(9):517-27. doi: 10.1016/j.eimc.2012.02.014. Epub 2012 Apr 30. Enferm Infecc Microbiol Clin. 2012. PMID: 22551653 Spanish.
Mitochondrial Haplogroups and Weight Gain After Initiating ART in Patients With HIV.
Berenguer J, Jarrín I, Bellón JM, Díez C, Jiménez-Sousa MA, López JC, Pinto-Martínez A, Moreno S, Montes ML, Iribarren JA, Orviz E, Portilla J, Villarroya F, Domingo P, Resino S; CoRIS Cohort. Berenguer J, et al. J Infect Dis. 2024 Aug 16;230(2):421-425. doi: 10.1093/infdis/jiae168. J Infect Dis. 2024. PMID: 38557859
Predictors of poor health-related quality of life among people living with HIV aged ≥60 years in the PISCIS cohort: Findings from the Vive+ project.
Bruguera A, Egea-Cortés L, Mesías-Gazmuri J, Palacio-Vieira J, Forero CG, Miranda C, Saumoy M, Fernández E, Navarro G, Orti A, Miró JM, Casabona J, Reyes-Urueña J; PISCS Study Group. Bruguera A, et al. HIV Med. 2024 Apr;25(4):424-439. doi: 10.1111/hiv.13590. Epub 2023 Dec 13. HIV Med. 2024. PMID: 38092529
Mortality and immunovirological outcomes in patients with advanced HIV disease on their first antiretroviral treatment: differential impact of antiretroviral regimens.
Burgos J, Moreno-Fornés S, Reyes-Urueña J, Bruguera A, Martín-Iguacel R, Raventos B, Llibre JM, Imaz A, Peraire J, Orti AJ, Dalmau D, Casabona J, Miró JM, Falcó V; PISCIS study group. Burgos J, et al. J Antimicrob Chemother. 2022 Dec 23;78(1):108-116. doi: 10.1093/jac/dkac361. J Antimicrob Chemother. 2022. PMID: 36308326
Impact of tenofovir on SARS-CoV-2 infection and severe outcomes among people living with HIV: a propensity score-matched study.
Nomah DK, Reyes-Urueña J, Díaz Y, Moreno S, Aceiton J, Bruguera A, Vivanco-Hidalgo RM, Casabona J, Domingo P, Navarro J, Imaz A, Deig E, Navarro G, Llibre JM, Miro JM; PISCIS study group. Nomah DK, et al. J Antimicrob Chemother. 2022 Jul 28;77(8):2265-2273. doi: 10.1093/jac/dkac177. J Antimicrob Chemother. 2022. PMID: 35678461 Free PMC article.
Epidemiological trends of HIV/HCV coinfection in Spain, 2015-2019.
Fanciulli C, Berenguer J, Busca C, Vivancos MJ, Téllez MJ, Domínguez L, Domingo P, Navarro J, Santos J, Iribarren JA, Morano L, Artero A, Moreno J, Rivero-Román A, Santos I, Giner L, Armiñanzas C, Montero M, Manzardo C, Cifuentes C, García C, Galindo MJ, Ferrero OL, Sanz J, de la Fuente B, Rodríguez C, Gaspar G, Pérez L, Losa JE, Force L, Veloso S, Martínez-Alfaro E, Jarrín I, De Miguel M, González Garcia J; GeSIDA 8514 Study Group. Fanciulli C, et al. HIV Med. 2022 Aug;23(7):705-716. doi: 10.1111/hiv.13229. Epub 2022 Jan 17. HIV Med. 2022. PMID: 35037379 Free PMC article.
Sociodemographic, clinical, and immunological factors associated with SARS-CoV-2 diagnosis and severe COVID-19 outcomes in people living with HIV: a retrospective cohort study.
Nomah DK, Reyes-Urueña J, Díaz Y, Moreno S, Aceiton J, Bruguera A, Vivanco-Hidalgo RM, Llibre JM, Domingo P, Falcó V, Imaz A, Cortés C, Force L, Letang E, Vilaró I, Casabona J, Miro JM; PISCIS study group. Nomah DK, et al. Lancet HIV. 2021 Nov;8(11):e701-e710. doi: 10.1016/S2352-3018(21)00240-X. Epub 2021 Oct 13. Lancet HIV. 2021. PMID: 34655549 Free PMC article.
Strategies to reengage patients lost to follow up in HIV care in high income countries, a scoping review.
Palacio-Vieira J, Reyes-Urueña JM, Imaz A, Bruguera A, Force L, Llaveria AO, Llibre JM, Vilaró I, Borràs FH, Falcó V, Riera M, Domingo P, de Lazzari E, Miró JM, Casabona J; PICIS study group. Palacio-Vieira J, et al. BMC Public Health. 2021 Aug 28;21(1):1596. doi: 10.1186/s12889-021-11613-y. BMC Public Health. 2021. PMID: 34454444 Free PMC article.
HIV/HBV coinfection: temporal trends and patient characteristics, Spain, 2002 to 2018.
Pérez-Latorre L, Berenguer J, Micán R, Montero M, Cifuentes C, Puig T, Sanz J, Ferrero OL, De La Fuente B, Rodríguez C, Reus S, Hernández-Quero J, Gaspar G, Pérez-Martínez L, García C, Force L, Veloso S, De Miguel M, Jarrín I, González-García J; GeSIDA 8514 Study Group. Pérez-Latorre L, et al. Euro Surveill. 2021 Jun;26(25):2000236. doi: 10.2807/1560-7917.ES.2021.26.25.2000236. Euro Surveill. 2021. PMID: 34169818 Free PMC article.
Lower expression of plasma-derived exosome miR-21 levels in HIV-1 elite controllers with decreasing CD4 T cell count.
Ruiz-de-León MJ, Jiménez-Sousa MA, Moreno S, García M, Gutiérrez-Rivas M, León A, Montero-Alonso M, González-García J, Resino S, Rallón N, Benito JM, Vallejo A; ECRIS Network integrated in the Spanish AIDS Research Network. Ruiz-de-León MJ, et al. J Microbiol Immunol Infect. 2019 Aug;52(4):667-671. doi: 10.1016/j.jmii.2018.07.007. Epub 2018 Aug 24. J Microbiol Immunol Infect. 2019. PMID: 30193823 Free article.
Relationship between plasma bilirubin level and oxidative stress markers in HIV-infected patients on atazanavir- vs. efavirenz-based antiretroviral therapy.
Estrada V, Monge S, Gómez-Garre MD, Sobrino P, Masiá M, Berenguer J, Portilla J, Viladés C, Martínez E, Blanco JR; CoRIS and the HIV Biobank integrated in the Spanish AIDS Research Network. Estrada V, et al. Among authors: vilades c. HIV Med. 2016 Oct;17(9):653-61. doi: 10.1111/hiv.12368. Epub 2016 Mar 3. HIV Med. 2016. PMID: 26935006 Free article.
Impact of late presentation of HIV infection on short-, mid- and long-term mortality and causes of death in a multicenter national cohort: 2004-2013.
Sobrino-Vegas P, Moreno S, Rubio R, Viciana P, Bernardino JI, Blanco JR, Bernal E, Asensi V, Pulido F, del Amo J, Hernando V; Cohorte de la Red de Investigación en Sida, Spain. Sobrino-Vegas P, et al. J Infect. 2016 May;72(5):587-96. doi: 10.1016/j.jinf.2016.01.017. Epub 2016 Feb 24. J Infect. 2016. PMID: 26920789 Free article.
Comparative effectiveness of immediate antiretroviral therapy versus CD4-based initiation in HIV-positive individuals in high-income countries: observational cohort study.
Lodi S, Phillips A, Logan R, Olson A, Costagliola D, Abgrall S, van Sighem A, Reiss P, Miró JM, Ferrer E, Justice A, Gandhi N, Bucher HC, Furrer H, Moreno S, Monge S, Touloumi G, Pantazis N, Sterne J, Young JG, Meyer L, Seng R, Dabis F, Vandehende MA, Pérez-Hoyos S, Jarrín I, Jose S, Sabin C, Hernán MA; HIV-CAUSAL Collaboration. Lodi S, et al. Lancet HIV. 2015 Aug;2(8):e335-43. doi: 10.1016/S2352-3018(15)00108-3. Epub 2015 Jul 7. Lancet HIV. 2015. PMID: 26423376 Free PMC article.
HIV/antiretroviral therapy-related lipodystrophy syndrome (HALS) is associated with higher RBP4 and lower omentin in plasma.
Peraire J, López-Dupla M, Alba V, Beltrán-Debón R, Martinez E, Domingo P, Asensi V, Leal M, Viladés C, Inza MI, Escoté X, Arnedo M, Mateo G, Valle-Garay E, Ferrando-Martinez S, Veloso S, Vendrell J, Gatell JM, Vidal F; HIV-1 Lipodystrophy Study Group. Peraire J, et al. Among authors: vilades c. Clin Microbiol Infect. 2015 Jul;21(7):711.e1-8. doi: 10.1016/j.cmi.2015.04.002. Epub 2015 Apr 14. Clin Microbiol Infect. 2015. PMID: 25882366 Free article.
Boosted lopinavir- versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes: a prospective study of HIV-infected individuals in high-income countries.
HIV-CAUSAL Collaboration; Cain LE, Phillips A, Olson A, Sabin C, Jose S, Justice A, Tate J, Logan R, Robins JM, Sterne JA, van Sighem A, Reiss P, Young J, Fehr J, Touloumi G, Paparizos V, Esteve A, Casabona J, Monge S, Moreno S, Seng R, Meyer L, Pérez-Hoyos S, Muga R, Dabis F, Vandenhende MA, Abgrall S, Costagliola D, Hernán MA. HIV-CAUSAL Collaboration, et al. Clin Infect Dis. 2015 Apr 15;60(8):1262-8. doi: 10.1093/cid/ciu1167. Epub 2015 Jan 6. Clin Infect Dis. 2015. PMID: 25567330 Free PMC article.
Incidence of hepatitis C virus (HCV) in a multicenter cohort of HIV-positive patients in Spain 2004-2011: increasing rates of HCV diagnosis but not of HCV seroconversions.
Sobrino-Vegas P, Monge Corella S, Serrano-Villar S, Gutiérrez F, Blanco JR, Santos I, del Romero J, Segura F, Portilla J, Guillén SM, del Amo J; CoRIS. Sobrino-Vegas P, et al. PLoS One. 2014 Dec 30;9(12):e116226. doi: 10.1371/journal.pone.0116226. eCollection 2014. PLoS One. 2014. PMID: 25549224 Free PMC article.
Differential body composition effects of protease inhibitors recommended for initial treatment of HIV infection: a randomized clinical trial.
Martinez E, Gonzalez-Cordon A, Ferrer E, Domingo P, Negredo E, Gutierrez F, Portilla J, Curran A, Podzamczer D, Ribera E, Murillas J, Bernardino JI, Santos I, Carton JA, Peraire J, Pich J, Deulofeu R, Perez I, Gatell JM; ATADAR Study Group. Martinez E, et al. Clin Infect Dis. 2015 Mar 1;60(5):811-20. doi: 10.1093/cid/ciu898. Epub 2014 Nov 10. Clin Infect Dis. 2015. PMID: 25389256 Free article. Clinical Trial.
Early lipid changes with atazanavir/ritonavir or darunavir/ritonavir.
Martinez E, Gonzalez-Cordon A, Ferrer E, Domingo P, Negredo E, Gutierrez F, Portilla J, Curran A, Podzamczer D, Murillas J, Bernardino JI, Santos I, Carton JA, Peraire J, Pich J, Perez I, Gatell JM; ATADAR Study Group. Martinez E, et al. HIV Med. 2014 Jul;15(6):330-8. doi: 10.1111/hiv.12121. Epub 2014 Jan 12. HIV Med. 2014. PMID: 24417772 Free article. Clinical Trial.
Compliance with national guidelines for HIV treatment and its association with mortality and treatment outcome: a study in a Spanish cohort.
Suárez-García I, Sobrino-Vegas P, Tejada A, Viciana P, Ribas M, Iribarren J, Díaz Menéndez M, Rivero M, Arazo P, Del Amo J, Moreno S; Cohort of the Spanish AIDS Research Network (CoRIS) study group. Suárez-García I, et al. HIV Med. 2014 Feb;15(2):86-97. doi: 10.1111/hiv.12078. Epub 2013 Sep 6. HIV Med. 2014. PMID: 24007468 Free article.
Definition of advanced age in HIV infection: looking for an age cut-off.
Blanco JR, Jarrín I, Vallejo M, Berenguer J, Solera C, Rubio R, Pulido F, Asensi V, del Amo J, Moreno S; CoRIS. Blanco JR, et al. AIDS Res Hum Retroviruses. 2012 Sep;28(9):1000-6. doi: 10.1089/AID.2011.0377. AIDS Res Hum Retroviruses. 2012. PMID: 22607516 Free PMC article.
The effect of efavirenz versus nevirapine-containing regimens on immunologic, virologic and clinical outcomes in a prospective observational study.
Cain LE, Phillips A, Lodi S, Sabin C, Bansi L, Justice A, Tate J, Logan R, Robins JM, Sterne JA, van Sighem A, de Wolf F, Bucher HC, Elzi L, Touloumi G, Vourli G, Esteve A, Casabona J, del Amo J, Moreno S, Seng R, Meyer L, Pérez-Hoyos S, Muga R, Abgrall S, Costagliola D, Hernán MA; HIV-CAUSAL Collaboration. Cain LE, et al. AIDS. 2012 Aug 24;26(13):1691-705. doi: 10.1097/QAD.0b013e328354f497. AIDS. 2012. PMID: 22546987 Free PMC article.
Impact of antiretroviral therapy on tuberculosis incidence among HIV-positive patients in high-income countries.
del Amo J, Moreno S, Bucher HC, Furrer H, Logan R, Sterne J, Pérez-Hoyos S, Jarrín I, Phillips A, Lodi S, van Sighem A, de Wolf W, Sabin C, Bansi L, Justice A, Goulet J, Miró JM, Ferrer E, Meyer L, Seng R, Toulomi G, Gargalianos P, Costagliola D, Abgrall S, Hernán MA; HIV-CAUSAL Collaboration. del Amo J, et al. Clin Infect Dis. 2012 May;54(9):1364-72. doi: 10.1093/cid/cis203. Epub 2012 Mar 28. Clin Infect Dis. 2012. PMID: 22460971 Free PMC article.
Zinc alpha-2 glycoprotein is implicated in dyslipidaemia in HIV-1-infected patients treated with antiretroviral drugs.
Ceperuelo-Mallafré V, Escoté X, Viladés C, Peraire J, Domingo P, Solano E, Sirvent JJ, Pastor R, Tinahones F, Leal M, Richart C, Vendrell J, Vidal F; HIV-1 Lipodystrophy Study Group; Alba V, Aguilar A, Auguet T, Chacón MR, López-Dupla M, Megia A, Miranda M, Olona M, Saurí A, Vargas M, Velasco I, Veloso S, Fontanet A, Gutiérrez M, Mateo G, Muñoz J, Sambeat MA. Ceperuelo-Mallafré V, et al. Among authors: vilades c. HIV Med. 2012 May;13(5):297-303. doi: 10.1111/j.1468-1293.2011.00976.x. Epub 2012 Jan 19. HIV Med. 2012. PMID: 22256965 Free article.
When to initiate combined antiretroviral therapy to reduce mortality and AIDS-defining illness in HIV-infected persons in developed countries: an observational study.
HIV-CAUSAL Collaboration; Cain LE, Logan R, Robins JM, Sterne JA, Sabin C, Bansi L, Justice A, Goulet J, van Sighem A, de Wolf F, Bucher HC, von Wyl V, Esteve A, Casabona J, del Amo J, Moreno S, Seng R, Meyer L, Perez-Hoyos S, Muga R, Lodi S, Lanoy E, Costagliola D, Hernan MA. HIV-CAUSAL Collaboration, et al. Ann Intern Med. 2011 Apr 19;154(8):509-15. doi: 10.7326/0003-4819-154-8-201104190-00001. Ann Intern Med. 2011. PMID: 21502648 Free PMC article.
A study of fatty acid binding protein 4 in HIV-1 infection and in combination antiretroviral therapy-related metabolic disturbances and lipodystrophy.
Escoté X, Megia A, López-Dupla M, Miranda M, Veloso S, Alba V, Domingo P, Pardo P, Viladés C, Peraire J, Giralt M, Richart C, Vendrell J, Vidal F; HIV-1 Lipodystrophy Study Group. Escoté X, et al. Among authors: vilades c. HIV Med. 2011 Aug;12(7):428-37. doi: 10.1111/j.1468-1293.2010.00903.x. Epub 2011 Jan 19. HIV Med. 2011. PMID: 21251185 Free article.
Sensitivity of seven HIV subtyping tools differs among subtypes/recombinants in the Spanish cohort of naïve HIV-infected patients (CoRIS).
Yebra G, de Mulder M, Martín L, Pérez-Cachafeiro S, Rodríguez C, Labarga P, García F, Tural C, Jaén A, Navarro G, Holguín A; Cohort of Spanish AIDS Research Network (CoRIS). Yebra G, et al. Antiviral Res. 2011 Jan;89(1):19-25. doi: 10.1016/j.antiviral.2010.10.008. Epub 2010 Nov 9. Antiviral Res. 2011. PMID: 21070813
Similar antiviral efficacy and tolerability between efavirenz and lopinavir/ritonavir, administered with abacavir/lamivudine (Kivexa), in antiretroviral-naïve patients: a 48-week, multicentre, randomized study (Lake Study).
Echeverría P, Negredo E, Carosi G, Gálvez J, Gómez JL, Ocampo A, Portilla J, Prieto A, López JC, Rubio R, Mariño A, Pedrol E, Viladés C, del Arco A, Moreno A, Bravo I, López-Blazquez R, Pérez-Alvarez N, Clotet B. Echeverría P, et al. Among authors: vilades c. Antiviral Res. 2010 Feb;85(2):403-8. doi: 10.1016/j.antiviral.2009.11.008. Epub 2009 Nov 24. Antiviral Res. 2010. PMID: 19941906 Clinical Trial.
The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals.
HIV-CAUSAL Collaboration; Ray M, Logan R, Sterne JA, Hernández-Díaz S, Robins JM, Sabin C, Bansi L, van Sighem A, de Wolf F, Costagliola D, Lanoy E, Bucher HC, von Wyl V, Esteve A, Casbona J, del Amo J, Moreno S, Justice A, Goulet J, Lodi S, Phillips A, Seng R, Meyer L, Pérez-Hoyos S, García de Olalla P, Hernán MA. HIV-CAUSAL Collaboration, et al. AIDS. 2010 Jan 2;24(1):123-37. doi: 10.1097/QAD.0b013e3283324283. AIDS. 2010. PMID: 19770621 Free PMC article.
Fosamprenavir (GW433908)/ritonavir in HIV-infected patients: efficacy and safety results from the Spanish Expanded Access Program.
Pérez-Elias MJ, Sánchez-Conde M, Soriano V, Mallolas J, Luque I, Rodríguez-Alcántara F; Fosamprenavir Expanded Access Program Group. Pérez-Elias MJ, et al. Enferm Infecc Microbiol Clin. 2009 Jan;27(1):28-32. doi: 10.1016/j.eimc.2008.05.002. Epub 2009 Jan 9. Enferm Infecc Microbiol Clin. 2009. PMID: 19218000 Clinical Trial.